Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.

Cancer Immunol Immunother. 2010 May;59(5):663-74. doi: 10.1007/s00262-009-0782-8. Epub 2009 Nov 5.

2.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
3.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

PMID:
22918924
4.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

5.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
6.

Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.

Hwang C, Sanda MG.

Curr Opin Mol Ther. 1999 Aug;1(4):471-9. Review.

PMID:
11713762
7.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
8.

CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.

Lubaroff DM, Karan D.

Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi: 10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Review.

PMID:
19166887
9.

Immunotherapeutics in development for prostate cancer.

Harzstark AL, Small EJ.

Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240. Epub 2009 Apr 2. Review.

10.

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL.

Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928. Review.

11.

Castrate-resistant prostate cancer: therapeutic strategies.

Harzstark AL, Small EJ.

Expert Opin Pharmacother. 2010 Apr;11(6):937-45. doi: 10.1517/14656561003677382. Review.

PMID:
20307219
12.

Poxviral vectors for cancer immunotherapy.

Kim JW, Gulley JL.

Expert Opin Biol Ther. 2012 Apr;12(4):463-78. doi: 10.1517/14712598.2012.668516. Review.

13.

Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.

Semin Oncol. 2012 Jun;39(3):296-304. doi: 10.1053/j.seminoncol.2012.02.010. Review.

14.

Molecular markers in prostate cancer. Part II: potential roles in management.

Agrawal S, Patil KP, Dunsmuir WD.

Asian J Androl. 2009 Jan;11(1):22-7. doi: 10.1038/aja.2008.23. Epub 2008 Dec 1. Review.

Supplemental Content

Support Center